Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Shares Climb 6.6 Percent on Strong Q4 Revenue Growth

NEW YORK, Feb. 22 (GenomeWeb News) - CombiMatrix today reported fourth quarter revenues of $3.6 million versus $522,000 in the year-ago period.


Shares in CombiMatrix were up 6.55 percent, or $.11, at $1.79 in mid-afternoon trading on the news.


Total receipts for the period included $2.3 million in previously deferred revenues recognized from CombiMatrix's completion of its R&D agreement with Toppan Printing.


R&D costs increased 25 percent to $1.7 million from $1.4 million in the year-ago period.


Net losses in the fourth quarter narrowed 57 percent to $1.8 million from $4.1 million, CombiMatrix said.


The unit had around $20.2 million in cash and short-term investments as of Dec.31.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.